(JAMA : Journal of the American Medical Association[TA])
84,448 results
  • Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment. [Journal Article]
    JAMA. 2026 Jul 14. [Online ahead of print]Buckley RF, Townsend DL, … Alzheimer’s Disease Neuroimaging Initiative, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies, Harvard Aging Brain Study (HABS), Health & Aging Brain Study – Health Disparities (HABS-HD), and Wisconsin Registry for Alzheimer’s Prevention (WRAP)JAMA
  • CONCLUSIONS: In a pooled sample of multiple selected cohorts of cognitively unimpaired older adults, higher plasma p-tau217 levels were consistently associated with increased risk of clinical progression and accelerated cognitive decline. By providing time-specific absolute risk estimates, these findings support the potential of p-tau217 for prognostic model development, with direct implications for future trial design. Further validation in unselected populations is needed to inform individual prognosis and clinical decision-making in cognitively unimpaired individuals.
  • Publisher Full Text (DOI)